XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
he company posted total income during Q2 FY24 at Rs. 12.86 crore
The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h
Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII)
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Subscribe To Our Newsletter & Stay Updated
